Business
uniQure Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting
LEXINGTON, Mass. and AMSTERDAM, Oct. 24, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative
About this update from Uniqure N.v.
[{"type":"text","content":"LEXINGTON, Mass. and AMSTERDAM, Oct. 24, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that 12 data presentations, including two oral presentations, will be delivered at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting being held October 24-27 in Brussels, Belgium. “Our multiple presentations at ESGCT demonstrate uniQure’s continued leadership in advancing important research within the field of gene therapy, as well as highlight our industry-leading expertise in AAV gene therapy manufacturing,” stated Richard Porter, Ph.D., Chief Business and Scientific Officer at uniQure. “We look forward to sharing these presentations that feature our technology and platform experience across numerous programs.” Specific details on uniQure’s presentations taking place at ESGCT include: Invited Talk Title: Update on U.S. Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s DiseasePresenter: Richard Porter, Chief Business and Scientific Officer, uniQureSession Title and Location: CNS & sensory diseases II, Session 10a, Shed 2ADate and Time: Friday, October 27, 8:30 a.m. GMT+2 Title: Gene therapy for C9ORF72-ALS reduces RNA toxicity and ameliorates behavioral phenotype in ALS mouse modelPresenter: Vanessa Zancanella, Sr. Scientist Global Research, uniQureSession Title and Location: CNS & sensory diseases I, Session 2c, Maison de la PosteDate and Time: Tuesday, October 24, 17:00 – 19:00 GMT+2 Title: Pivotal safety studies for AMT-260, a novel AAV9-dual microRNA-based vector targeting GRIK2 for the treatment of temporal lobe epilepsy (Poster #433)Presenter: Nick Pearson, Sr. Director Toxicology & Translational Safety, Non-Clinical, uniQure Poster Session Date and Time: Wednesday, October 25, 17:00 – 18:15, Thursday, October 26, 20:30 – 21:30 GMT+2 Title: Production of low cross-packaging AAV capsid libraries in insect cells (Poster #166)Presenter: Bas Bosma, Scientific Leader, Technology Innovation, uniQurePoster Session Date and Time: Wednesday, October 25, 18:15 – 19:30, Thursday October 26, 19:30 – 20:30 GMT+2 Title: Multiplexed comparison of rationally-designed AAV CNS capsids in vivo (Poster #181)Presenter: Elena Pimentel, Scientist, Technology Innovation, uniQurePo...